The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy

Journal of Obstetrics and Gynaecology Canada

Volumn 33, Issue 2, 2011, Pages 153-158

  Ebrahimi, Neda ^a   Vohra, Sabina ^a   Gedeon, Christelle ^a   Akoury, Hani ^b   Bernstein, Paul ^c   Pairaudeau, Nicholas ^d   Cormier, Johanne ^e   Dontigny, Lorraine ^e   Arsenault, Marc Yvon ^e   Fortin, Claude ^e   Goyet, Martine ^e   Lafortune, Chantal ^e   Lalande, Johanne ^e   Beauchamp, Coralie ^e   Engel, Francis ^e   Fortin, Anne ^e   Taddio, Anna ^a   Einarson, Tom ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d NORTH YORK GENERAL HOSPITAL   (Canada)

^e LaSalle Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE ACETATE PLUS PRAMOCAINE; ANTIINFLAMMATORY AGENT; HYDROCORTISONE; LOCAL ANESTHETIC AGENT; MORPHOLINE DERIVATIVE; PROCTOFOAM-HC;

ADULT; ARTICLE; BIRTH WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FETUS OUTCOME; GESTATIONAL AGE; HEMORRHOID; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEWBORN; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURITY; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; FETUS DEVELOPMENT; PREGNANCY;

ADULT; ANESTHETICS, LOCAL; ANTI-INFLAMMATORY AGENTS; BIRTH WEIGHT; DRUG COMBINATIONS; FEMALE; FETAL DEVELOPMENT; HEMORRHOIDS; HUMANS; HYDROCORTISONE; MORPHOLINES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, THIRD;

EID: 79960091586     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)34802-2     Document Type: Article

References (35)

1. Gordon P.H., Nivatvongs S. Principles and practice of surgery for the colon, rectum and anus 1999, 193-196. Quality Medical Publishing, St. Louis. 2nd ed.
2. Dykes S., Bordeianou L. Hemorrhoids and incontinence. Advances in reconstructive vaginal surgery 2007, 320-323. Lippincott Williams & Wilkins, Philadelphia. S.R. Kovac, C.W. Zimmerman (Eds.).
3. Hancock R., Koren G., Einarson A., Ungar W. The effectiveness of teratology information services. Reprod Toxicol 2007, 23:125-132.
4. Product information Proctofoam-HC rectal anti-inflammatory foam, hydrocortisone acetate, pramoxine HCI 1976, Duchesnay Inc, Bainville, Quebec.
5. Williams obstetrics 2005, 91-119. Fetal growth and development, New York: McGraw Hil, Chapter 4. 22nd ed. F.G. Cunningham, K.J. Leveno, S.L. Bloom, J.C. Hauth, D.J. Rouse, C.Y. Spong (Eds.).
6. US Department of Health and Human Services The health benefits of smoking cessation 1990, Office on Smoking and Health, Rockville, MD, DHHS Publication No. (CDC) 90-8416.
7. Gagnon R. Placental insufficiency and its consequences. Eur J Obstet Gynecol Reprod Biol 2003, 110:S99-S107.
8. Walsh R.A., Lowe J.B., Hopkins P.J. Quitting smoking in pregnancy. Med J Aus 2001, 175:320-323.
9. Koren G. Medication safety in pregnancy and breastfeeding 2007, 21-23. McGraw Hill, New York.
10. Butler N.R., Goldstein H., Ross E.M. Cigarette smoking in pregnancy: its influence on birthweight and perinatal mortality. Br Med J 1972, 15:127-130.
11. Drugdex evaluations: pramoxine. Micromedex healthcare series [Internet database] 2008, Thomson Reuters, Greenwood Village, CO.
12. Noojin R.O. Tronothande hydrochloride (pramoxine hydrochloride) in the control of pruritus. Postgrad Med 1954, 16:453-455.
13. Peal L., Karp M. A new surface anesthetic agent: tronothane. Ill Med J 1953, 104(5):299-301.
14. Drug information for the health care professional (USP DI) 1996, United States Pharmacopeial Convention, Inc, Rockville, MD. 16 th ed.
15. Product information: tronolane, pramoxine 1996, Ross Labs, Consumer Products, Columbus, OH.
16. Ritchie J.M., Greengard P. On the mode of action of local anesthetics. Annu Rev Pharmacol 1966, 6:405-430.
17. Product information 2001, naropin. Astra Zeneca.
18. Santos A.C., Karpel B., Noble G. The placental transfer and fetal effects of levobupivacaine, racemic bupivacaine, and ropivacaine. Anesthesiology 1999, 90:1698-1703.
19. Product information: xylocaine 2000, AstraZeneca.
20. LaBorde J.B. Developmental toxicity evaluation of lidocaine in CD rats. Teratology 1988, 37:472.
21. Fujinaga M., Mazze R.I. Reproductive and teratogenic effects of lidocaine in Sprague-Dawley rats. Anesthesiology 1986, 65:626-632.
22. Tuvemo T., Willdeck-Lund G. Smooth muscle effects of lidocaine, prilocaine, bupivacaine and etiodocaine on the human umbilical artery. Acta Anaesthesiol Scand 1982, 26:104-107.
23. Teramo K., Benowitz N., Heymann M.A., Kahanpää K., Siimes A., Rudolph A.M. Effects of lidocaine on heart rate, blood pressure and electrocorticogram in fetal sheep. Am J Obstet Gynecol 1974, 118:943-949.
24. Fleming J.A., Lambert T.F., Walker A.M. The effects of bupivacaine on the umbilical circulation and placental gas exchange in the fetal lamb. Anesth Analg 1987, 66(H):1121-1126.
25. Noren H., Kallfelt B., Lindblom B. Influence of bupivacaine and morphine on human umbilical arteries and veins in vitro. Acta Obstet Gynecol Scand 1990, 69:87-91.
26. Park-Wyllie L., Mazzotta P., Pastuszak A., Moretti M.E., Beique L., Hunnisett L., et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000, 62:385-392.
27. Schatz M., Zeiger R.S., Harden K., Hoffman C.C., Chilingar L., Petitti D. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 1997, 100:3016.
28. Mygind H., Thulstrup A.M., Pedersen L., Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroids in pregnancy. Acta Obstet Gynecol Scand 2002, 81:234-239.
29. Banks B.A., Cnaan A., Morgan M.A., Parer J.T., Merrill J.D., Ballard P.L., et al. Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. Am J Obstet Gynecol 1999, 181:709-717.
30. Thorp J.A., Jones P.G., Knox E., Clark R.H.I. Does antenatal corticosteroid therapy affect birth weight and head circumference?. Obstet Gynecol 2002, 99:101-108.
31. Keith L.G., Oleszczuk J.J., Keith D.M. Multiple gestation: reflections on epidemiology, causes, and consequences. Int J Fertil Womens Med 2000, 45:206-214.
32. Backe B. Maternal smoking and age: effect on birthweight and risk for small-for-gestational age births. Acta Obstet Gynecol Scand 1993, 72:172-176.
33. Statistics Canada Table 102-4510. Mean and median birth weight (live births), by sex, Canada, provinces and territories, annual. CANSIM (database) 2010, Available at, Accessed November 19. http://cansim2.statcan.gc.ca/cgi-win/cnsmcgi.exe?Lang=E&RootDir=CH/&ResultTemplate=Cn/CII_&Array_Pick=1&ArrayId=1024510.
34. Tromm A., Möllmann H., Barth J., Hochhaus G., Krieg M., Bigalke C., et al. Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. J Clin Pharmacol 2001, 41:536-541.
35. Vohra S., Akoury H., Bernstein P., Einarson T.R., Pairaudeau N., Taddio A., et al. The effectiveness of Proctofoam-HC for treatment of hemorrhoids in late pregnancy. J Obstet Gynaecol Can 2009, 31:654-659.